Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age

Adults aged 50–64 years have a high incidence of symptomatic influenza associated with substantial disease and economic burden each year. We conducted a randomized, controlled trial to compare the immunogenicity and safety of an adjuvanted quadrivalent inactivated influenza vaccine (aIIV4; n = 1027)...

Full description

Bibliographic Details
Main Authors: Airi Poder, Janine Oberije, Jay Meyer, Peter Heymer, Deborah Molrine, Eve Versage, Leah Isakov, Qiuhong Zhang, Matthew Hohenboken
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Vaccines
Subjects:
influenza
adjuvanted influenza vaccine
chronic medical condition
age 50–64 years
middle-aged adults
Online Access:https://www.mdpi.com/2076-393X/11/10/1528

Internet

https://www.mdpi.com/2076-393X/11/10/1528

Similar Items